Stoke Therapeutics (NASDAQ:STOK) Research Coverage Started at Chardan Capital

Chardan Capital started coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note released on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $24.00 target price on the stock.

STOK has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Leerink Partners began coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price for the company. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $21.29.

Stoke Therapeutics Stock Up 3.4 %

NASDAQ STOK opened at $11.68 on Friday. Stoke Therapeutics has a twelve month low of $4.09 and a twelve month high of $17.58. The stock has a market cap of $618.65 million, a P/E ratio of -5.56 and a beta of 0.95. The company’s 50-day simple moving average is $12.48 and its 200 day simple moving average is $13.54.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Research analysts anticipate that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,170 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the sale, the chief executive officer now owns 68,671 shares of the company’s stock, valued at approximately $877,615.38. This represents a 8.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Jonathan Allan sold 9,696 shares of Stoke Therapeutics stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $123,914.88. Following the transaction, the general counsel now directly owns 35,142 shares in the company, valued at approximately $449,114.76. This represents a 21.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock worth $809,421 over the last ninety days. Company insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently modified their holdings of the business. Lynx1 Capital Management LP increased its position in shares of Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after acquiring an additional 1,488,371 shares in the last quarter. RTW Investments LP boosted its position in shares of Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after buying an additional 427,447 shares during the period. State Street Corp grew its holdings in shares of Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after buying an additional 137,145 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its position in Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after buying an additional 1,123,500 shares during the last quarter. Finally, Marshall Wace LLP lifted its stake in Stoke Therapeutics by 550.1% in the 2nd quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock valued at $15,686,000 after acquiring an additional 982,451 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.